Related Experiment Videos
Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Robert J Jones1, Christopher J Twelves
1Cancer Research UK, Department of Medical Oncology, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK. R.Jones@beatson.gla.ac.uk
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
Pemetrexed, an antifolate anticancer drug, shows promising activity against solid tumors. Further research is ongoing to determine its full potential in patient care.
Area of Science:
- Oncology
- Pharmacology
Background:
- Pemetrexed is a novel antifolate chemotherapy agent.
- Understanding its activation, mechanism, and pharmacokinetics is crucial.
Purpose of the Study:
- To detail the activation, mode of action, and pharmacokinetics of pemetrexed.
- To review toxicity and anticancer activity from Phase I and II trials.
- To present early combination studies and speculate on future clinical roles.
Main Methods:
- Phase I, II, and early combination trials of pemetrexed.
- Evaluation of drug activation, mechanism of action, and pharmacokinetics.
- Assessment of toxicity and antitumor activity in various solid tumors.
Main Results:
- Pemetrexed exhibits a defined spectrum of toxicity.
- Demonstrated anticancer activity in several solid tumor types.
- Early combination studies show potential therapeutic benefits.
Conclusions:
- Pemetrexed demonstrates promising antitumor activity in multiple solid tumors.
- Further Phase III studies are anticipated to confirm its efficacy.
- Pemetrexed may play a significant future role in cancer treatment.